<DOC>
	<DOCNO>NCT01611506</DOCNO>
	<brief_summary>RATIONALE : Radiotherapy currently efficient way induce pathologic response , associate favorable prognosis localize tumor . Novel radiotherapy technique associate significantly less toxicity traditional radiation protocol permit avoid toxicity adjacent organ . Established chemotherapy regimen , cisplatin capecitabine , monoclonal antibody , cetuximab , block tumor growth different way . Giving radiation therapy together cisplatin cetuximab surgery aim induce pathological response improve prognosis surgery . PURPOSE : This phase I trial study side effect best dose radiation therapy give together cisplatin cetuximab treat patient undergo surgery locally advance gastric cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Cetuximab Radiation Patients With Localized Gastric Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary â€¢ To determine maximum tolerate dose radio-chemo-immunotherapy - patient localize locally advanced gastric cancer Secondary - To determine efficacy , measure major histopathological response rate ( tumor regression grade 1 2 ) - Metabolic response - Secondary resectability - R-0 resection rate - Surgical morbidity - Toxicity - Overall survival - Time local systemic progression R0-resection - Feasibility OUTLINE : Prospective , multicenter , open-label dose escalate phase Ib trial During induction chemo-immuno-therapy , patient receive cetuximab IV 1-2 hour day 1 , cisplatin IV 1 hour day 1 capecitabine twice daily per os even day 1 morning day 15 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Radiotherapy start end third cycle chemotherapy perform concomitantly weekly cetuximab cisplatin . Cohorts 3-6 patient receive escalate dos radiotherapy ( level 36/39.6/45 Gy ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede maximum 3 12 patient experience dose-limiting toxicity . Gastric resection perform within 4-6 week completion neoadjuvant treatment . 4-6 week surgery , 3 cycle chemo-immuno-therapy administer patient recover surgery treatment consider feasible investigator . For note : Cisplatin may replace oxaliplatin induction chemotherapy postoperative chemotherapy . In case oxaliplatin use replace cisplatin induction chemotherapy , replacement cisplatin oxaliplatin radio-chemo-immunotherapy may also consider investigator . Capecitabine may replace infusional 5-FU day 1-5 every 21 day case contraindication capecitabine . In case cisplatin capecitabine replace , 4 cycle FOLFOX-6 ( d-l leucovorin , follow 5-FU bolus continuous infusion 46 hour every 2 week administer combination cetuximab ) . Patients undergo tumor tissue blood sample collection periodically biological study . Samples analyze major histopathological response . After completion study treatment , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically proven , localize ( UICC stage III , T12 , N12 T3N0 ) locally advanced ( UICC stage III , T34 , N+ ) gastric Siewert Type II III GEjunction adenocarcinoma . Tumor stage determine thoracoabdominal CTscan , EUS , well mandatory laparoscopy rule peritoneal carcinomatosis within 28 day prior registration . ECOGstatus 01 Hematologic , liver , renal function normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment Peritoneal carcinomatosis , diagnose mandatory laparoscopy distant metastasis Concurrent treatment experimental drug anticancer therapy , treatment within clinical trial within 30 day prior trial entry Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV , myocardial infarction within last 12 month , unstable angina pectoris , significant arrhythmia ) Active uncontrolled infection . Definitive contraindication use corticosteroid premedication Prior systemic ( chemo target ) treatment . Prior radiotherapy upper abdomen Any contraindication treatment cetuximab , capecitabine cisplatin Any concomitant medication contraindicate use trial drug , sorivudin brivudin HER2 expression , determine immunohistochemistry ( IHC 3+ ) combination IHC FISH ( IHC 2+/FISH+ ) Previous malignancy within 5 year , exception adequately treat cervical carcinoma situ localize nonmelanoma skin cancer Known hypersensitivity study drug ( cetuximab , cisplatin capecitabine ) component trial drug Known deficit dihydropyrimidine dehydrogenase Preexisting peripheral neuropathy &gt; grade I Due know interaction coumarin antagonist ( e.g . warfarin ) capecitabine patient require oral anticoagulation include study switch oral anticoagulation low molecular weight heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>